GENE ONLINE|News &
BeiGene launches IPO on Shanghai’s STAR market to raise $3B
BeiGene Ltd announces the third round of its initial public offering (IPO) on the STAR market of Shanghai Stock Exchange to raise US $3.5 billion. The global biotech company, based in Beijing, China offers around 115 million ordinary shares, representing 8.62% of its total outstanding shares.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
